Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: a systematic review and meta-analysis of randomized trials
With nearly half of Americans saying weight loss is a goal for them, its no wonder that interest in GLP-1 medications has been on the rise
Wegovy is FDA-approved to treat obesity, while Ozempic and Rybelsus are approved to treat type 2 diabetes
Its a GLP-1 receptor agonist, a medication that mimics the incretin hormones in the body, which lowers blood sugar levels and has effects on appetite regulation
The following protocols are designed for three distinct populations and provide specific, actionable programming that you can implement immediately
Food and Drug Administration (FDA) announced that the shortage of semaglutide injections had been resolved, leading to the removal of these products from the agencys drug shortage list